Core Viewpoint - The article summarizes significant rating changes from Wall Street, highlighting companies with upgraded, downgraded, and newly initiated ratings, which are crucial for investors to consider. Upgraded Ratings - Shopify (SHOP) upgraded from Hold to Buy by Cowen Group with a target price of $159, citing valuation advantages as the stock has dropped 30% this year and strong quarterly performance provides an attractive entry point [2] - BorgWarner (BWA) upgraded from Hold to Buy by Deutsche Bank, with the target price raised from $46 to $82, noting the company's critical transformation into the AI data center market [2] - Analog Devices (ADI) upgraded from Equal Weight to Overweight by Barclays, with the target price increased from $315 to $375, emphasizing its high industrial business share in the analog chip sector [2] - MercadoLibre (MELI) upgraded from Neutral to Overweight by JPMorgan, with the target price raised from $2650 to $2800, due to more attractive valuations following recent stock price weakness [2] - Fastly (FSLY) upgraded from Market Perform to Outperform by William Blair, with no target price set, highlighting exceptional quarterly performance driven by increased AI traffic contributions [2] Downgraded Ratings - Coinbase (COIN) downgraded from Buy to Sell by Monness Crespi, with a target price of $120, as the firm revised down earnings forecasts ahead of its quarterly report, deeming previous assumptions about a steady recovery in cryptocurrency by 2026 as overly optimistic [3] - Kraft Heinz (KHC) downgraded from Neutral to Underweight by JPMorgan, with the target price lowered from $24 to $22, despite exceeding fourth-quarter expectations, as 2026 organic sales and profit outlooks fall short of market expectations [3] - Icon (ICLR) downgraded from Neutral to Underperform by Bank of America, with a significant target price cut from $195 to $75, due to an internal investigation revealing potential revenue inflation [3] - Inspire Medical (INSP) downgraded from Overweight to Equal Weight by Wells Fargo, with the target price reduced from $145 to $70, citing uncertainties in reimbursement policies affecting stock prices [4] - Humana (HUM) downgraded from Outperform to Market Perform by Royal Bank of Canada, with the target price lowered from $322 to $189, as the risk-reward balance has become neutral following strong growth amid reimbursement policy uncertainties [4] Initiated Coverage - Microchip Technology (MCHP) initiated coverage with a Neutral rating and a target price of $80 by Barclays, noting risks of market share loss in the microcontroller sector [5] - ON Semiconductor (ON) initiated coverage with a Neutral rating and a target price of $75 by Barclays, highlighting high exposure to the Chinese market and automotive sector as a suppressive factor [5] - Sterling Infrastructure (STRL) initiated coverage with a Buy rating and a target price of $486 by Stifel, as the largest earthmoving contractor in the U.S. is expected to benefit from long-term growth themes [5] - D-Wave Quantum (QBTS) initiated coverage with a Buy rating and no target price set by Cowen Group, citing the company's leading position in quantum annealing driving growth and high margins [5] - Immunome (IMNM) initiated coverage with a Buy rating and a target price of $40 by H.C. Wainwright, as the company builds a differentiated pipeline in oncology with significant advantages in solid and hematologic tumors [5]

Core Insights - Immunome, Inc. (NASDAQ:IMNM) is recognized as one of the top 14 booming stocks to buy, with shares increasing by 48% over the last three months [1][2] - The stock's positive performance is largely attributed to optimistic projections regarding its potential to treat desmoid tumors [2] Clinical Trial Results - On December 15, Immunome, Inc. announced favorable topline results from the Phase 3 RINGSIDE trial, showing an 84% reduction in the likelihood of death or disease progression compared to a placebo [3] - The trial involved 156 patients, with approximately 56% experiencing tumor shrinkage or disappearance, compared to only 9% in the placebo group [4] Market Outlook and Analyst Ratings - Following the trial results, Guggenheim raised its price target for Immunome from $25 to $35 while maintaining a Buy rating, anticipating FDA approval for Varegacestat and a significant market share in the desmoid tumors sector [5] - Evercore ISI Group and Lake Street also increased their price targets to $40 from $18 and $32 from $22, respectively, while reiterating their Outperform and Buy ratings [5] - Wall Street analysts have a consensus Strong Buy rating for the stock, with an average one-year price target of $33.20, indicating a potential upside of 61.40% as of January 12 [6]

Company Overview - Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotech company focused on developing targeted cancer treatments, with a leading drug candidate in late-stage testing and another in early clinical trials [1] - The company has a pipeline that includes therapies aimed at treating solid tumors with more precise approaches [1] Recent Developments - On December 15, 2025, Immunome announced strong results from the Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors [1] - The drug demonstrated an 84% reduction in the risk of disease progression or death compared to placebo, a 56% response rate versus 9% for placebo, and an 83% reduction in tumor volume, with mostly mild to moderate side effects [2] Future Plans - Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026 [2] - The primary investigator of the RINGSIDE trial, Dr. Mrinal M. Gounder, highlighted the significant benefits of varegacestat, suggesting it could become the standard of care for desmoid tumors [2]

Economic Overview - Weaker-than-expected Chinese economic data negatively impacts global growth prospects, with November industrial production easing to +4.8% y/y from +4.9% y/y in October, below expectations of +5.0% y/y. Retail sales rose only +1.3% y/y, the smallest increase in 2.75 years, and new home prices fell 0.39% m/m, marking the 30th consecutive month of declines [1] - In the US, the December Empire manufacturing survey unexpectedly contracted by -22.6 points to -3.9, weaker than the expected 10.0, while the December NAHB housing market index rose +1 to an 8-month high of 39, aligning with expectations [2] Federal Reserve and Interest Rates - Dovish comments from Fed officials suggest a supportive environment for stocks, with Fed Governor Stephen Miran stating that the current policy stance is unnecessarily restrictive, citing a benign inflation outlook and labor market concerns. NY Fed President John Williams indicated a shift towards a neutral monetary policy stance [3] - The outlook for lower interest rates is bolstered by a decrease in the 10-year T-note yield to 4.17%, with expectations of Fed-friendly economic news this week [4] Stock Market Performance - Stock indexes experienced declines, with the S&P 500 falling to a 2-week low and the Nasdaq 100 sliding to a 2.5-week low, driven by concerns over AI spending and disappointing outlooks from tech companies like Oracle and Broadcom [5] - The S&P 500 Index is down by -0.15%, the Dow Jones by -0.24%, and the Nasdaq 100 by -0.26% [6] Upcoming Economic Data - Market focus will be on upcoming US economic data, including expectations for a +50,000 increase in November nonfarm payrolls and a 4.5% unemployment rate. November average hourly earnings are expected to rise by +0.3% m/m and +3.6% y/y [7] Global Market Trends - Overseas stock markets are mixed, with the Euro Stoxx 50 up +0.56% and China's Shanghai Composite down -0.55%. Japan's Nikkei Stock 225 closed down -1.31% [8] Sector-Specific Movements - KLA Corp leads chip makers with a rise of more than +3% after an upgrade from Jeffries, while ServiceNow is down more than -10% following a downgrade by KeyBanc Capital Markets [13][16] - Cryptocurrency-exposed stocks are experiencing significant declines, with Bitcoin down more than -4% to a 2-week low, impacting companies like Riot Platforms and Galaxy Digital Holdings [14] - Energy stocks are also falling, with WTI crude oil down more than -1% to a 1.75-month low, affecting companies like APA Corp and Devon Energy [15]

Group 1 - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points on Monday [1] - Kyverna Therapeutics Inc shares surged 31% to $11.49 following the announcement of topline data from the KYSA-8 Phase 2 trial [2][3] - The KYSA-8 trial involved mivocabtagene autoleucel (miv-cel), a CAR T-cell therapy targeting stiff person syndrome [1] Group 2 - Other notable stock gains included Beneficient, which increased by 29.3% to $6.21, and Immunome Inc, which rose 25.5% to $24.56 after positive results from its Phase 3 trial [3] - Falcon's Beyond Global Inc gained 14% to $12.83, while XBP Global Holdings Inc surged 11.5% to $6.39 [3] - Almonty Industries Inc announced a voluntary withdrawal of its base shelf prospectus, leading to a 9.1% increase in its stock price to $7.38 [3]

Economic Indicators - The Dec NAHB housing market index is expected to increase by +1 to 39 [1] - Nov nonfarm payrolls are expected to increase by +50,000, with the unemployment rate at 4.5% [1] - Nov average hourly earnings are expected to rise by +0.3% m/m and +3.6% y/y [1] - Oct retail sales are expected to be up +0.1% m/m, and retail sales ex-autos are expected to be up +0.2% m/m [1] - The Dec S&P manufacturing PMI is expected to decline by -0.2 to 52.0 [1] - Weekly initial unemployment claims are expected to fall -11,000 to 225,000 [1] - Nov CPI is expected to be +3.1% y/y, and Nov core CPI is expected to be +3.0% y/y [1] - Nov existing home sales are expected to be up +1.2% m/m to 4.15 million [1] - The University of Michigan Dec consumer sentiment index is expected to be revised upward by +0.2 to 53.5 [1] Global Economic News - China's Nov industrial production eased to +4.8% y/y from +4.9% y/y in Oct, below expectations of +5.0% y/y [2] - China's Nov retail sales rose +1.3% y/y, weaker than expectations of +2.9% y/y, marking the smallest increase in 2.75 years [2] - China's new home prices fell 0.39% m/m, marking the 30th consecutive month of declines [2] Stock Market Performance - US stock indexes are climbing, with the S&P 500 Index up by +0.39%, Dow Jones up by +0.27%, and Nasdaq 100 up by +0.50% [5] - The markets are discounting a 27% chance that the FOMC will cut the fed funds target range by 25 bp at the next meeting [5] - Mining stocks are moving higher, with gold and copper up more than +1% and silver up more than +3% [11] - KLA Corp is up more than +4% after an upgrade from Jeffries, leading chip makers higher [10] - ZIM Integrated Shipping Services is up more than +5% after a reported bid from MSC to purchase the company [12] Interest Rates and Bond Market - The 10-year T-note yield is down -2.0 bp to 4.165%, with T-notes climbing due to dovish economic indicators [7] - The yield curve has steepened since the last FOMC meeting, indicating bearish sentiment for T-note prices [8] - European government bond yields are moving lower, with the 10-year German bund yield down -1.7 bp to 2.840% [9]

Analyst Ratings Overview - Jefferies analyst Jonathan Petersen initiated coverage on Iron Mountain Incorporated (IRM) with a Buy rating and a price target of $120, while shares closed at $99.89 [6] - Citigroup analyst Ben Mohr initiated coverage on GATX Corporation (GATX) with a Buy rating and a price target of $201, with shares closing at $172.07 [6] - Evercore ISI Group analyst Elizabeth Suzuki initiated coverage on Humana Inc. (HUM) with an In-Line rating and a price target of $295, while shares closed at $252.66 [6] - Goldman Sachs analyst Salveen Richter initiated coverage on Immunome, Inc. (IMNM) with a Buy rating and a price target of $26, with shares closing at $9.39 [6] - GLJ Research analyst Austin Wang initiated coverage on Argan, Inc. (AGX) with a Hold rating and a price target of $251, while shares closed at $260.64 [6]

Core Insights - Voyager Therapeutics reported a quarterly loss of $0.57 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.48, marking an earnings surprise of -18.75% [1] - The company generated revenues of $5.2 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 55.43%, and a significant decline from $29.58 million in the same quarter last year [2] - Voyager Therapeutics shares have decreased by approximately 40.4% year-to-date, contrasting with the S&P 500's gain of 7.1% [3] Company Performance - Over the last four quarters, Voyager Therapeutics has only surpassed consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.48 on revenues of $11.24 million, and for the current fiscal year, it is -$1.99 on revenues of $44.08 million [7] - The estimate revisions trend for Voyager Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Viewpoint - The market anticipates Absci Corporation (ABSI) to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $0.19 per share, reflecting a year-over-year change of +13.6%, while revenues are expected to reach $2.32 million, an increase of 82.7% from the previous year [3]. - The consensus EPS estimate has been revised 11.36% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Absci is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +12.07%, suggesting a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which indicates a neutral outlook [12]. Historical Performance - In the last reported quarter, Absci was expected to post a loss of $0.23 per share but delivered a loss of -$0.21, resulting in a surprise of +8.70% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Immunome, Inc. is expected to report a loss of $0.52 per share for the same quarter, with revenues projected at $2.47 million, up 4.7% year-over-year [18]. - Immunome's consensus EPS estimate has been revised down by 0.7% over the last 30 days, but it has an Earnings ESP of +15.92%, combined with a Zacks Rank of 4, indicating challenges in predicting an earnings beat [19].

Company Performance - Jazz Pharmaceuticals reported a quarterly loss of $8.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $6.12, and a significant decline from earnings of $5.3 per share a year ago, indicating an earnings surprise of -34.80% [1] - The company posted revenues of $1.05 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.26%, but showing a slight increase from year-ago revenues of $1.02 billion [2] - Over the last four quarters, Jazz has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Jazz shares have declined approximately 5.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $5.08 on revenues of $1.11 billion, and for the current fiscal year, it is $4.93 on revenues of $4.24 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Jazz belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]